|
1) Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009; 100: 9-16
|
|
|
|
2) Soe-Lin S, Apte SS, Andriopoulos B Jr, et al. Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci U S A. 2009; 106: 5960-5
|
|
|
|
|
|
3) Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306: 2090-3
|
|
|
|
|
|
4) Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480: 147-50
|
|
|
|
|
|
5) Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276: 7806-10
|
|
|
|
|
|
6) Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology. 2007; 46: 1291-301
|
|
|
|
|
|
7) Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008; 40: 569-71
|
|
|
|
|
|
8) Kawabata H, Fleming RE, Gui D, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 2005; 105: 376-81
|
|
|
|
|
|
9) Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003; 361: 669-73
|
|
|
|
|
|
10) Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004; 36: 77-82
|
|
|
|
|
|
11) Andriopoulos B, Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41: 482-7
|
|
|
|
|
|
12) Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009; 41: 478-81
|
|
|
|
|
|
13) Truksa J, Peng H, Lee P, et al. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A. 2006; 103: 10289-93
|
|
|
|
|
|
14) Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008; 111: 924-31
|
|
|
|
|
|
15) Kanda J, Mizumoto C, Kawabata H, et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica. 2008; 93: 1550-4
|
|
|
|
|
|
16) Weizer-Stern O, Adamsky K, Amariglio N, et al. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Am J Hematol. 2006; 81: 479-83
|
|
|
|
|
|
17) Weizer-Stern O, Adamsky K, Amariglio N, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol. 2006; 135: 129-38
|
|
|
|
|
|
18) Kattamis A, Papassotiriou I, Palaiologou D, et al. The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 2006; 91: 809-12
|
|
|
|
|
|
19) Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol. 2004; 124: 123-4
|
|
|
|
|
|
20) Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988; 71: 1124-9
|
|
|
|
|
|
21) Van Wyck DB, Popp RA, Foxley J, et al. Spontaneous iron overload in alpha-thalassemic mice. Blood. 1984; 64: 263-6
|
|
|
|
|
|
22) Pippard MJ, Callender ST, Warner GT, et al. Iron absorption and loading in beta-thalassaemia intermedia. Lancet. 1979; 2: 819-21
|
|
|
|
|
|
23) de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med. 1979; 300: 5-8
|
|
|
|
|
|
24) Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood. 2005; 105: 4103-5
|
|
|
|
|
|
25) Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006; 38: 531-9
|
|
|
|
|
|
26) Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007; 13: 1096-101
|
|
|
|
|
|
27) Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009; 114: 181-6
|
|
|
|
|
|
28) Ramirez JM, Schaad O, Durual S, et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol. 2009; 144: 251-62
|
|
|
|
|
|
29) Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood. 2008; 112: 5241-4
|
|
|
|
|
|
30) Murphy PT, Mitra S, Gleeson M, et al. Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol. 2009; 144: 451-2
|
|
|
|
|
|
31) Winder A, Lefkowitz R, Ghoti H, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol. 2008; 142: 669-71
|
|
|
|
|
|
32) Mariani R, Pelucchi S, Pozzi M, et al. Reduced expression of hepcidin in patients with myelodysplastic syndrome and myelofibrosis: the causes might be more heterogeneous than in thalassaemia. Br J Haematol. 2008; 143: 746-7
|
|
|
|
|
|
33) Finkenstedt A, Bianchi P, Theurl I, et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol. 2009; 144: 789-93
|
|
|
|
|
|
34) Sahlstedt L, Ebeling F, von Bonsdorff L, et al. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol. 2001; 113: 836-8
|
|
|
|
|
|
35) Marx JJ. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol. 2002; 15: 411-26
|
|
|
|
|
|
36) Pieracci FM, Barie PS. Iron and the risk of infection. Surg Infect(Larchmt). 2005; 6 Suppl 1: S41-6
|
|
|
|
|
|
37) Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22: 538-43
|
|
|
|
|
|
38) Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331: 567-73
|
|
|
|
|
|
39) Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med. 1995; 332: 918-22
|
|
|
|
|
|
40) Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res. 2007; 31 Suppl 3: S7-9
|
|
|
|
|